Patient Advocacy at New BeiGene Facility

Newton Guerin, IWMF President & CEO, joined leaders of patient advocacy organizations throughout the U.S. to celebrate the grand opening of BeiGene’s flagship U.S. Biologics Manufacturing and Clinical R&D facility in Hopewell, NJ. The opening is the culmination of a three-year, $800 million project to expand BeiGene’s integrated manufacturing and R&D footprint in the United States. Newton Guerin is pictured above with Jen Branstetter, Executive Director, North America Corporate Affairs, BeiGene, during a tour of this new facility.

The day’s schedule also offered a Patient Advocacy Organization Breakfast where advocacy partners came together to talk through challenges around accessibility and affordability of medical care along with strategies to address increasing awareness, enrollment, and participation in clinical trials.

All of us with IWMF greatly appreciate our partnership with BeiGene as they continue to engage with advocacy partners to support access to care, innovative treatments, and support for people with cancer and their care partners.